ライフサイエンスコーパス: macrovesicular

1 On biopsy, all considered macrovesicular and 50% considered microvesicular steatos

2 totoxic effects in exposed larvae, including macrovesicular and microvesicular hepatic steatosis, as

3 e and markedly abnormal liver histology with macrovesicular and microvesicular steatosis, fatty Kupff

4 After 4 weeks of ethanol feeding, macrovesicular fat accumulation and accumulation of trig

5 rmethiazole, an inhibitor of CYP2E1, lowered macrovesicular fat accumulation, inhibited oxidative str

6 2E1-knockout mice via an adenovirus restored macrovesicular fat accumulation.

7 uction of p38a alone was sufficient to cause macrovesicular fatty liver.

8 sed serum alanine aminotransferase activity, macrovesicular hepatic steatosis, hepatic inflammatory g

9 er, which partially coincides with the outer macrovesicular layer, whereas exocyst components SEC-5,

10 teatosis characterized by microvesicular and macrovesicular lipid accumulation and increased triglyce

11 epatic steatosis characterized by micro- and macrovesicular lipid accumulation.

12 epatic steatosis characterized by micro- and macrovesicular lipid accumulation.

13 Ethanol feeding induced accumulation of macrovesicular lipid vacuoles to the greatest extent in

14 Longer cold ischemia time and large droplet macrovesicular steatosis ( 20%) were identified as indep

15 Longer cold ischemia time and large droplet macrovesicular steatosis (>=20%) were identified as inde

16 Only macrovesicular steatosis (MaS) significantly impacted PP

17 elow -10 HU correlated with greater than 30% macrovesicular steatosis (unacceptable for liver transpl

18 osis and inflammation were strongly reduced (macrovesicular steatosis -34%; microvesicular steatosis

19 KO mice exhibited severe macrovesicular steatosis and 5 to 6-fold higher serum al

20 omosome 18 a QTL regulating liver micro- and macrovesicular steatosis and inflammation, independently

21 intrahepatic cytokine and chemokine release, macrovesicular steatosis and liver damage were attenuate

22 Histologically, there is moderate to severe macrovesicular steatosis and lobular hepatitis with necr

23 months, knockout mice developed spontaneous macrovesicular steatosis and predominantly periportal mo

24 Donor livers with macrovesicular steatosis are disproportionately not tran

25 and classified based on amount of allograft macrovesicular steatosis at time of OLT.

26 Degree of histologic macrovesicular steatosis correlated well with LAI (r = 0

27 death donors over 50 years old, donors with macrovesicular steatosis greater than 30% on liver biops

28 LAI correctly predicted degree of macrovesicular steatosis in 38 (90%) of 42 cases.

29 Macrovesicular steatosis in greater than 30% of hepatocy

30 t not C(8)/C(10) feeding, induced periportal macrovesicular steatosis in Sirt5KO mice.

31 k-based model to quantify microvesicular and macrovesicular steatosis in the liver on hematoxylin-eos

32 d undue risk aversion, SRTR now accounts for macrovesicular steatosis in the SRTR risk-adjustment mod

33 Whether and what degree of graft macrovesicular steatosis is safe for both recipient and

34 crovesicular steatosis to the characteristic macrovesicular steatosis observed in clinical NASH and/o

35 United States, we assessed (1) the impact of macrovesicular steatosis on deceased donor yield (define

36 Increasing levels of macrovesicular steatosis on donor liver biopsy predicted

37 er biopsy predicted lower organ yield: >=31% macrovesicular steatosis on liver biopsy was associated

38 hough unenhanced CT quantifies the degree of macrovesicular steatosis relatively well, it may preclud

39 ific posttransplant outcome assessments when macrovesicular steatosis was added to the risk-adjustmen

40 The liver graft with severe macrovesicular steatosis was donated from a 25-year-old

41 ydrogenase (LCAD), also developed periportal macrovesicular steatosis when fed coconut oil, confirmin

42 ion analysis was used to correlate degree of macrovesicular steatosis with both LAI and BMI.

43 lipid accumulation in the form of micro and macrovesicular steatosis, and induction of cytochrome P4

44 ifferentiate the areas of microvesicular and macrovesicular steatosis, and to quantify the recognized

45 tocytes display features of NAFLD, including macrovesicular steatosis, ballooning, and necroapoptosis

46 All patients had mild macrovesicular steatosis, but only 1 patient had signifi

47 in donor, GRWR in recipient), with up to 20% macrovesicular steatosis, does not compromise graft func

48 nsulin levels, and reduced HFD-induced liver macrovesicular steatosis, hypertrophy, inflammation, and

49 (HFD) feeding resulted in NAFLD with massive macrovesicular steatosis, modest hepatic and adipose tis

50 without (Group B; <10%, n = 531) significant macrovesicular steatosis, on pre- or intraoperative biop

51 urrently excluded because of the presence of macrovesicular steatosis.

52 ed biopsy specimens and determined degree of macrovesicular steatosis.

53 sy to distinguish between microvesicular and macrovesicular steatosis.

54 parenchymal necrosis with microvesicular and macrovesicular steatosis.

55 gh-carbohydrate, fat-free diet and converted macrovesicular to microvesicular steatosis in B6.V-Lep(o